European Medicines Agency Accepts Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis
For Trade and Medical Media Only
Mundipharma today announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for rezafungin for the treatment of invasive candidiasis in adult patients. The MAA is based on results from the pivotal ReSTORE Phase III clinical trial, which demonstrated statistical non-inferiority of rezafungin dosed once weekly when compared to the current standard of care, caspofungin, dosed once daily. This trial provides evidence of efficacy and safety of rezafungin as potential first-line treatment for candidemia and invasive candidiasis.1
Invasive candidiasis is a severe, life-threatening systemic Candida infection of the bloodstream and/or deep/visceral tissues.2 Despite currently available treatments, the mortality rate for patients with invasive candidiasis remains high at up to 40%.3 There is a real need for new treatment options to address this serious disease, especially as there has been no significant progress in treatment over the last decade.
“Rezafungin, as a next generation echinocandin, represents the first advancement in the treatment of invasive Candida infections in a very long time. If approved, the treatment could bring new hope for critically ill, vulnerable patients battling with this deadly disease in the EU,“ said Brian Sheehan, Ph.D., Chief Scientific Officer at Mundipharma. “We are pleased that the EMA has accepted our marketing authorisation application for rezafungin, and we look forward to working with the EMA to bring this medicine to patients.”
Rezafungin has already been granted Orphan Drug Designation for its use in the treatment of invasive candidiasis in both the EU and US.4,5 A New Drug Application was recently submitted to the US Food and Drug Administration (FDA) for the treatment of candidemia and invasive candidiasis the USA. The FDA has previously identified rezafungin as a Qualified Infectious Disease Product (QIDP), which grants both Fast Track and Priority Review status.
Cidara has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan.
About Invasive Candidiasis
Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available treatments, the mortality rate for patients with invasive candidiasis is as high as 40%.3 IC is characterised as a severe, life-threatening systemic Candida infection of the bloodstream and/or deep/visceral tissues, known as candidemia and deep-seated tissue candidiasis.2
About Rezafungin
Rezafungin is a next-generation, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara has completed a Phase III clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial).6
In this ReSTORE trial, rezafungin met the primary endpoint for the European Medicines Agency (EMA) Marketing Authorization Application (MAA) submission of global cure at Day 14, and also met the primary endpoint for the U.S. Food and Drug Administration (FDA) New Drug Application (NDA) submission of all-cause mortality at Day 30. Both of these results demonstrated statistical non-inferiority of rezafungin dosed once-weekly, versus caspofungin dosed once-daily, which is the current standard of care. Rezafungin was generally well tolerated and had a similar safety profile to caspofungin.6
Cidara is also currently conducting a second Phase III clinical trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).
About Mundipharma
Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas. Our guiding principles, centered around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit www.mundipharma.com.
SciA-RZF-2200053
Date of preparation: August 2022
References
1 Thompson, G.R. et al, ReSTORE: Efficacy and Safety Results of the Phase 3, Noninferiority Trial of Rezafungin in the Treatment of Candidemia and/or Invasive Candidiasis, Abstract presented at ECCMID 2022
2 Cortes JA, Corrales IF. Invasive Candidiasis: Epidemiology and Risk Factors. November 2018. Available at https://www.intechopen.com/chapters/64365. Last accessed June 2022.
3 Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015;373:1445-1456.
4 U.S. Food & Drug Administration. Search Orphan Drug Designations and Approvals. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=%20507215 . Last accessed July 2022
5 European Commission. Community Register of orphan medicinal products. Available at: https://ec.europa.eu/health/documents/community-register/html/o2385.htm. Last accessed July 2022.
6 Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis. Available at https://www.mundipharma.com/Mundipharma-and-Cidara-Therapeutics-Announce-First-Presentation-of-Results-from-Global-Phase-3-ReSTORE-Trial-of-Rezafungin-for-Treatment-of-Candidemia-and/or-Invasive-Candidiasis-Demonstrating-its-Positive-Efficacy-and-Safety-Profile
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005377/en/
Contact information
MEDIA CONTACT
Jan Milton-Edwards
Mundipharma
+44-7341-739-984
jan.milton-edwards@mundipharma.com
Tara Lanigan
Mundipharma
+44-7918-970301
tara.lanigan@mundipharma.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esri COP28 LinkedIn Livestream Featuring: City of Sydney, Australia11.12.2023 18:01:00 CET | Press release
Esri: Date: Thursday, December 14, 2023 Time: 3:00 p.m. PST/6:00 p.m. EST Register Here Moderator: Brett Dixon, Esri Asia Pacific Spatial Industry Specialist & Business Leader Panelists: Matt Sund, City of Sydney Spatial Information Services Manager Karen Sweeney, City of Sydney Urban Forestry Manager Esri, a world leader in Geographic Information Systems (GIS) software solutions, is hosting a LinkedIn livestream on Thurs., December 14 featuring the City of Sydney, Australia. During the livestream, leaders from the City of Sydney will discuss their novel approach to advancing tree equity, no matter where their citizens live, along with increasing biodiversity in trees and the wildlife that rely on them. Rapid growth in greater Sydney has resulted in the loss of biodiversity and green, shady places. In the past decade, more than half of greater Sydney’s neighborhoods have lost urban forest cover, as experts warn that suburbs lacking sufficient tree cover may become unlivable. Now, the s
Obsidian Security Recognized as Strong Performer by Independent Research Firm11.12.2023 17:18:00 CET | Press release
We’re thrilled to share that Obsidian Security has been named a Strong Performer while receiving the highest scores possible across five criteria in The Forrester Wave™: SaaS Security Posture Management, Q4 2023 – the first Forrester Wave(™) report to be released in the SaaS Security and Posture Management (SSPM) category. Forrestergave the Obsidian Posture Management module the highest scores possible in the configuration drift detection and SaaS app configuration templates criteria. Additionally, the Obsidian Integration Risk Management module received the highest possible score in the connected apps criterion. Forrester also gave Obsidian the highest score possible in the IAM administration criterion supported by Obsidian Advanced Threat Mitigation module. The Forrester report recognized Obsidian as a vendor providing “a single, modular platform” for SaaS Security and Posture Management. The Obsidian Advanced Threat Mitigation module covers authentication monitoring and remediation,
Transition Industries LLC and Macquarie Group Announce Marketing Agreement for Low Carbon Methanol Project in Sinaloa, Mexico11.12.2023 15:13:00 CET | Press release
Transition Industries LLC announced at COP 28 that it has entered into a Master Services and Marketing Agreement (MSMA) with Macquarie Commodities Trading, an affiliate of Macquarie Group’s Commodities and Global Markets business (“Macquarie” / “CGM”), for its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico (“Pacifico Mexinol” or the “Project”). When it commences operations, Pacifico Mexinol is expected to be one of the largest single low carbon chemicals facilities in the world - producing approximately 300,000 MT of green methanol from captured carbon and green hydrogen and 1.8 million MT of blue methanol per year from natural gas with carbon capture. Under the terms of the MSMA, Macquarie is responsible for marketing all the production from Pacifico Mexinol to customers on a global basis in accordance with methanol offtake agreements, the provisioning of financial hedging services as required by the Project, and supporting
New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life11.12.2023 15:00:00 CET | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). Researchers analysed baseline data collected prior to initiation of study treatment and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS). “CTCL is a chronic, life-long condition. Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors. “The data provide new insights into the burdens of living with CTC
Battery Manufacturer Hithium Opens New 28 GWh Intelligent Production Plant11.12.2023 15:00:00 CET | Press release
Stationary energy storage expert Hithium will release 28 GWh planned production capacity successively at first stage of Phase 1 of its new base in Chongqing, China. The new plant is designed in line with "Intelligent Manufacturing 4.0" standards, including a 26% increase in automation over the typical "Intelligent Manufacturing 3.0" production system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211098435/en/ Hithium Chongqing production plant (Photo: Business Wire) Hithium’s automation gains at Chongqing have resulted in an overall efficiency jump of 30%, as well as cost reductions amounting to a quarter of production overhead, delivering a significant lead in manufacturing competitiveness. Built with an investment of RMB13 billion ($1.8 billion), the site covers 800,000 m2 and is located in the Tongliang high-tech zone. The new capacity aims at helping to meet global demand for what is expected to be 720GW of energy s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom